Skip to main content

Advertisement

Table 4 Mean and SEM values for the safety parameters measured in the control and treated groups at baseline and during the 12 week treatment period. Dose levels of phospholipids, EPA, DHA and choline are given at the end of the table

From: Effects of a purified krill oil phospholipid rich in long-chain omega-3 fatty acids on cardiovascular disease risk factors in non-human primates with naturally occurring diabetes type-2 and dyslipidemia

Parameter Group Value Baseline Week after start of treatment
4 8 12
Alanine transaminase (ALT) (U/L) Control Mean 128 127 182 101
SEM 59 54 103 32
Treated Mean 86 87 65 75
SEM 50 24 2 14
Aspartate Aminotransferase (AST) (U/L) Control Mean 36 32 44 33
SEM 6 4 13 4
Treated Mean 32 27 30 42
SEM 9 5 6 11
Alkaline Phosphatase (ALP) (U/L) Control Mean 225 221 226 220
SEM 37 40 46 56
Treated Mean 162 166 140 169
SEM 37 44 36 68
Blood Urea Nitrogen (BUN) (mmol/L) Control Mean 6.69 6.13 6.46 6.29
SEM 0.46 0.69 0.67 0.69
Treated Mean 6.16 5.65 5.95 5.65
SEM 0.04 0.52 0.63 0.54
Creatinine (μmol/L) Control Mean 62 64 63 61
SEM 23 23 23 23
Treated Mean 77 74 80 76
SEM 5.2 5.6 5.3 5.4
Uric acid (μmol/L) Control Mean 6.07 4.90 5.37 6.40
SEM 0.17 0.12 0.12 0.25
Treated Mean 7.00 9.17 6.70 7.13
SEM 1.04 2.99 1.17 1.33
Cystatin C (mg/L) Control Mean 1.23 1.17 1.15 1.10
SEM 0.21 0.23 0.22 0.16
Treated Mean 1.21 1.23 1.26 1.24
SEM 0.01 0.10 0.10 0.10
Prothromin time (PT) (sec) Control Mean 9.90 9.8 10.5 10.6
SEM 0.36 0.40 0.52 0.64
Treated Mean 10.1 10.0 10.6 10.8
SEM 0.29 0.36 0.32 0.20
Activated Partial Thromboplastin time (APTT) (sec) Control Mean 19.3 19.7 19.1 18.9
SEM 0.18 0.47 0.73 1.22
Treated Mean 21.0 21.9 21.5 21.5
SEM 1.93 1.85 2.18 2.55
Thrombin Time (TT) (sec) Control Mean 30.5 29.8 27.9 26.8
SEM 0.52 1.73 1.54 2.18
Treated Mean 29.3 28.8 28.7 28.1
SEM 0.92 2.80 1.91 1.34
Dose (mg phospholipids/kg bw/day) 50 150 450
Dose (mg [EPA/DHA]/kg bw/day) 9.35/5.48 28.1/16.4 84.2/49.3
Dose (mg choline/kg bw/day) 5.83 17.5 52.5